Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Stephens Investment Management Group LLC

Stephens Investment Management Group LLC lessened its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 0.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,738,482 shares of the specialty pharmaceutical company's stock after selling 13,586 shares during the period. Stephens Investment Management Group LLC owned about 3.11% of Supernus Pharmaceuticals worth $56,935,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of SUPN. Raiffeisen Bank International AG acquired a new position in shares of Supernus Pharmaceuticals in the fourth quarter valued at approximately $25,000. Financial Management Professionals Inc. acquired a new position in shares of Supernus Pharmaceuticals in the first quarter valued at approximately $30,000. Versant Capital Management Inc raised its position in shares of Supernus Pharmaceuticals by 6,931.3% in the first quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock valued at $37,000 after buying an additional 1,109 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Supernus Pharmaceuticals in the fourth quarter valued at approximately $42,000. Finally, Mark Sheptoff Financial Planning LLC acquired a new position in shares of Supernus Pharmaceuticals in the fourth quarter valued at approximately $52,000.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday.

Supernus Pharmaceuticals Stock Performance

Supernus Pharmaceuticals stock traded up $0.01 during trading on Wednesday, reaching $33.52. The company had a trading volume of 1,200,451 shares, compared to its average volume of 492,171. Supernus Pharmaceuticals, Inc. has a 12-month low of $27.05 and a 12-month high of $40.28. The stock's 50 day moving average price is $32.36 and its two-hundred day moving average price is $33.70. The firm has a market capitalization of $1.88 billion, a price-to-earnings ratio of 30.20 and a beta of 0.70.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.